Non-Darwinian dynamics in therapy-induced cancer drug resistance

Development of drug resistance, the prime cause of failure in cancer therapy, is commonly explained by the selection of resistant mutant cancer cells. However, dynamic non-genetic heterogeneity of clonal cell populations continuously produces meta-stable phenotypic variants (persisters), some of which represent stem-like states that confer resistance. Even without genetic mutations, Darwinian selection can expand these resistant variants, which would explain the invariably rapid emergence of stem-like resistant cells. Here, using quantitative measurements and modeling we show that appearance of multi-drug resistance in HL60 leukemic cells following treatment with vincristine is not explained by Darwinian selection but by Lamarckian induction. Single-cell longitudinal monitoring confirms the induction of multi-drug resistance in individual cells. Associated transcriptome changes indicate a lasting stress-response consistent with a drug-induced switch between high-dimensional cancer attractors. Resistance-induction correlates with Wnt-pathway up-regulation and is suppressed by β-catenin knock-down, revealing a new opportunity for early therapeutic intervention against resistance development.

[1]  Paul A. Wiggins,et al.  Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state , 2011, Proceedings of the National Academy of Sciences.

[2]  Michael L. Wang,et al.  Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide , 2010, The Journal of Biological Chemistry.

[3]  Hannah H. Chang,et al.  Non-genetic heterogeneity — a mutation-independent driving force for the somatic evolution of tumours , 2009, Nature Reviews Genetics.

[4]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[5]  W. McGuire,et al.  Response of human breast cancer cells to heat shock and chemotherapeutic drugs. , 1992, Cancer research.

[6]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[7]  Corinne Laplace-Builhé,et al.  The Origin of Phenotypic Heterogeneity in a Clonal Cell Population In Vitro , 2007, PloS one.

[8]  M. Notarbartolo,et al.  Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). , 2002, Cancer letters.

[9]  Jason I. Herschkowitz,et al.  The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo , 2011, Proceedings of the National Academy of Sciences.

[10]  Scott E. Kern,et al.  Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis , 2011, Nature.

[11]  Hannah H. Chang,et al.  Transcriptome-wide noise controls lineage choice in mammalian progenitor cells , 2008, Nature.

[12]  I. Pastan,et al.  Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. , 1990, The Journal of biological chemistry.

[13]  K. Guegler,et al.  Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation , 2004, Nature Biotechnology.

[14]  W. Birchmeier,et al.  Wnt signaling in stem and cancer stem cells. , 2013, Current opinion in cell biology.

[15]  Sui Huang,et al.  Gene Expression Dynamics Inspector (GEDI): for integrative analysis of expression profiles , 2003, Bioinform..

[16]  I. Ial,et al.  Nature Communications , 2010, Nature Cell Biology.

[17]  O. Legrand,et al.  Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. , 1998, Blood.

[18]  C. Waddington.  Canalization of Development and the Inheritance of Acquired Characters , 1942, Nature.

[19]  Hannah H. Chang,et al.  Multistable and multistep dynamics in neutrophil differentiation , 2006, BMC Cell Biology.

[20]  J. Zalcberg,et al.  Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.

[21]  K. Scotto.  Transcriptional regulation of ABC drug transporters , 2003, Oncogene.

[22]  Sui Huang.  The molecular and mathematical basis of Waddington's epigenetic landscape: A framework for post‐Darwinian biology? , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[24]  Camille Stephan-Otto Attolini,et al.  Evolutionary Theory of Cancer , 2009, Annals of the New York Academy of Sciences.

[25]  W. Sellers,et al.  Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance , 2013, Nature.

[26]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[27]  Zhiping Weng,et al.  Gene set enrichment analysis: performance evaluation and usage guidelines , 2012, Briefings Bioinform..

[28]  Jae-Seung Shim,et al.  Stochastic acquisition of a stem cell-like state and drug tolerance in leukemia cells stressed by radiation , 2011, International journal of hematology.

[29]  Rashi Iyer,et al.  Low dose, low-LET ionizing radiation-induced radioadaptation and associated early responses in unirradiated cells. , 2002, Mutation research.

[30]  F. Holstege,et al.  Specific inhibition of gene expression using a stably integrated, inducible small‐interfering‐RNA vector , 2003, EMBO reports.

[31]  S. Correa,et al.  Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia , 2012, BMC Cancer.

[32]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[33]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[34]  A. Donnenberg,et al.  Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis , 2005, Journal of clinical pharmacology.

[35]  Yolanda Fernández,et al.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer , 2012, Nature Medicine.

[36]  Ida Landini,et al.  Overcoming tumor multidrug resistance using drugs able to evade P‐glycoprotein or to exploit its expression , 2012, Medicinal research reviews.

[37]  M. Burt,et al.  Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. , 1999, Clinical Cancer Research.

[38]  E. Mayr.  Lamarck revisited , 1972, Journal of the history of biology.

[39]  S. Rosenzweig,et al.  Acquired resistance to drugs targeting receptor tyrosine kinases. , 2012, Biochemical pharmacology.

[40]  M. Pigliucci.  Genotype–phenotype mapping and the end of the ‘genes as blueprint’ metaphor , 2010, Philosophical Transactions of the Royal Society B: Biological Sciences.

[41]  R. Bernards,et al.  MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling , 2012, Cell.

[42]  I. Roninson,et al.  Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. , 1993, Journal of the National Cancer Institute.

[43]  Sui Huang,et al.  On the intrinsic inevitability of cancer: from foetal to fatal attraction. , 2011, Seminars in cancer biology.

[44]  Eric C. Sorenson,et al.  Imatinib Potentiates Anti-tumor T Cell Responses in Gastrointestinal Stromal Tumor through the Inhibition of Ido Nih Public Access Author Manuscript , 2022 .

[45]  Su Jin Lee,et al.  Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report , 2012, Journal of clinical medicine research.

[46]  K. Kaneko,et al.  Adaptive Response of a Gene Network to Environmental Changes by Fitness-Induced Attractor Selection , 2006, PloS one.

[47]  R. Milo,et al.  Dynamic Proteomics of Individual Cancer Cells in Response to a Drug , 2008, Science.

[48]  Guy S. Salvesen,et al.  SnapShot: Caspases , 2011, Cell.

[49]  Gabriel S. Eichler,et al.  Cell fates as high-dimensional attractor states of a complex gene regulatory network. , 2005, Physical review letters.

[50]  Clinton C. Dawson,et al.  “Persisters”: Survival at the Cellular Level , 2011, PLoS pathogens.

[51]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[52]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[53]  T. Elston,et al.  Stochasticity in gene expression: from theories to phenotypes , 2005, Nature Reviews Genetics.

[54]  L. Sommer,et al.  Probing transcription-specific outputs of β-catenin in vivo. , 2011, Genes & development.

[55]  Jean-Pierre Gillet,et al.  Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.

[56]  Judith Campisi,et al.  Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B , 2012, Nature Medicine.

[57]  Sui Huang,et al.  Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. , 2012, Progress in biophysics and molecular biology.

[58]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[59]  C. Hinshelwood,et al.  Integration of Cell Reactions , 1963, Nature.

[60]  Daniel A Charlebois,et al.  Gene expression noise facilitates adaptation and drug resistance independently of mutation. , 2011, Physical review letters.

[61]  J. Baselga,et al.  687 Beta-catenin Confers Resistance to PI3K and AKT Inhibitors and Subverts FOXO3a to Promote Metastasis in Colon Cancer , 2012 .

[62]  K. Hoek,et al.  Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.

[63]  D. Alberts,et al.  Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. , 1986, Cancer research.

[64]  B. Ogretmen,et al.  Identification and characterization of the MDR1 promoter-enhancing factor 1 (MEF1) in the multidrug resistant HL60/VCR human acute myeloid leukemia cell line. , 2000, Biochemistry.

[65]  Erik Aurell,et al.  Quasi-potential landscape in complex multi-stable systems , 2012, Journal of The Royal Society Interface.

[66]  Chava Kimchi-Sarfaty,et al.  P-glycoprotein: from genomics to mechanism , 2003, Oncogene.

[67]  A. Feinberg,et al.  The epigenetic progenitor origin of human cancer , 2006, Nature Reviews Genetics.

[68]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[69]  William Pao,et al.  Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.

[70]  T. Fojo,et al.  Gene rearrangement: a novel mechanism for MDR-1 gene activation. , 1997, The Journal of clinical investigation.

[71]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.